NCT02303678View on ClinicalTrials.gov

D2C7 for Adult Patients With Recurrent Malignant Glioma

PHASE1CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

May 5, 2015

Primary Completion Date

May 9, 2019

Study Completion Date

March 25, 2024

Conditions
Malignant GliomaBrain Tumor, Recurrent
Interventions
DRUG

D2C7-IT

D2C7-IT is a single-chain fragment variable (scFv) monoclonal antibody (Mab) fragment immunotoxin with high binding affinity for both EGFRwt- and EGFRvIII-expressing glioblastoma multiforme (GBM) cells.

Trial Locations (1)

27710

Preston Robert Tisch Brain Tumor Center at Duke, Durham

All Listed Sponsors
lead

Darell Bigner

OTHER

NCT02303678 - D2C7 for Adult Patients With Recurrent Malignant Glioma | Biotech Hunter | Biotech Hunter